CMS issues permanent J-code for Vyjuvek

Key takeaways:

• The J-code will simplify billing and reimbursement for Vyjuvek.
• Vyjuvek is the first FDA-approved treatment for dystrophic epidermolysis bullosa.

Vyjuvek, the first FDA-approved treatment for dystrophic epidermolysis bullosa, has received a permanent J-code from the Centers for Medicare and Medicaid Services, Krystal Biotech announced in a press release.

The J-code simplifies billing and reimbursement for Vyjuvek (beremagene geperpavec-svdt), a herpes simplex virus type 1 vector-based gene therapy indicated in the treatment of epidermolysis bullosa wounds.

“The permanent J-code will help ensure efficient and accurate reimbursement of Vyjuvek and further enable us to bring this important treatment to DEB patients in need,” Krish S. Krishnan, MBA, chairman and CEO of Krystal Biotech, said in the release.

The FDA approved the topical gene therapy in May 2023, making it the first available treatment for the rare, severe disease that can lead to skin infections, fibrosis and squamous cell carcinoma.